The abstract is read at the publisher; the summary is JClub's.
Personalized mRNA cancer vaccines show an inflection point in immunotherapy: combined with pembrolizumab they improved outcomes in high-risk melanoma, but as single-agent therapy in high-risk colorectal cancer they failed.
- Why it matters: Checkpoint inhibitors can release antitumor immunity, yet therapeutic vaccines are needed to steer immune targeting toward tumors, especially earlier when tumor burden is low.
- What they did: The work highlights personalized vaccination directing T cells to tumor-specific neoantigens, paired with checkpoint blockade to sustain T-cell function, and an NCI-led international initiative to test diverse vaccine strategies including mRNA over 2–3 years.
- The result: These developments suggest a next generation approach that both removes inhibitory signals and increasingly directs where the immune system attacks, while accelerating vaccine discovery and translation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.